The Canadian Biomarker Integration Network in Depression (CAN-BIND): Magnetic Resonance Imaging Protocols
- PMID: 30840428
- PMCID: PMC6606427
- DOI: 10.1503/jpn.180036
The Canadian Biomarker Integration Network in Depression (CAN-BIND): Magnetic Resonance Imaging Protocols
Abstract
Studies of clinical populations that combine MRI data generated at multiple sites are increasingly common. The Canadian Biomarker Integration Network in Depression (CAN-BIND; www.canbind.ca) is a national depression research program that includes multimodal neuroimaging collected at several sites across Canada. The purpose of the current paper is to provide detailed information on the imaging protocols used in a number of CAN-BIND studies. The CAN-BIND program implemented a series of platform-specific MRI protocols, including a suite of prescribed structural and functional MRI sequences supported by real-time monitoring for adherence and quality control. The imaging data are retained in an established informatics and databasing platform. Approximately 1300 participants are being recruited, including almost 1000 with depression. These include participants treated with antidepressant medications, transcranial magnetic stimulation, cognitive behavioural therapy and cognitive remediation therapy. Our ability to analyze the large number of imaging variables available may be limited by the sample size of the substudies. The CAN-BIND program includes a multimodal imaging database supported by extensive clinical, demographic, neuropsychological and biological data from people with major depression. It is a resource for Canadian investigators who are interested in understanding whether aspects of neuroimaging — alone or in combination with other variables — can predict the outcomes of various treatment modalities.
© 2019 Joule Inc. or its licensors
Conflict of interest statement
G. MacQueen reports consultancy/speaker fees from Lundbeck, Pfizer, Johnson & Johnson and Janssen, outside the submitted work. B. Frey reports grants and personal fees from Pfizer and personal fees from Sunovion, outside the submitted work. R. Milev reports grants, nonfinancial support and honoraria from Lundbeck, Janssen and Pfizer; personal fees and honoraria from Sunovion, Shire, Allergan and Otsuka; grants from Boehringer Ingelheim; and grants from the Ontario Brain Institute, the Canadian Institutes for Health Research and CAN-BIND, outside the submitted work. F. Vila-Rodriguez reports nonfinancial support from Magventure during the conduct of the study; grants from the Canadian Institutes for Health Research, Brain Canada, the Michael Smith Foundation for Health Research, and the Vancouver Coastal Health Research Institute; and personal fees from Janssen, outside the submitted work. S. Rizvi reports grants from Pfizer Canada, outside the submitted work. S. Strother reports grants from Canadian Biomarker Integration Network in Depression during the conduct of the study and grants from Ontario Brain Institute, outside the submitted work. He is also the chief scientific officer of the neuroimaging data analysis company ADMdx, Inc (www. admdx.com), which specializes in brain image analysis to enable diagnosis, prognosis and drug effect detection for Alzheimer disease and various other forms of dementia. R. Lam reports grants from Canadian Institutes of Health Research during the conduct of the study; grants from Asia-Pacific Economic Cooperation, VGH-UBCH Foundation, BC LEading Edge Endowment Fund, Janssen, Lundbeck, Pfizer and St. Jude Medical, outside the submitted work; personal fees from Allergan, Akili, CME Institute, Canadian Network for Mood and Anxiety Treatments, Janssen, Lundbeck, Lundbeck Institute, Pfizer, Otsuka, Medscape and Hansoh, outside the submitted work; travel expenses from Asia-Pacific Economic Cooperation outside the submitted work; and stock options from Mind Mental Health Technologies.
Figures



Similar articles
-
Discovering Biomarkers for Antidepressant Response: Protocol From the Canadian Biomarker Integration Network in Depression (CAN-BIND) and Clinical Characteristics of the First Patient CohortRW Lam et al. BMC Psychiatry 16, 105. PMID 27084692.ClinicalTrials.gov identifier NCT01655706 . Registered July 27, 2012.
-
Functional Brain Imaging: An Evidence-Based AnalysisMedical Advisory Secretariat. Ont Health Technol Assess Ser 6 (22), 1-79. PMID 23074493.There is evidence to indicate that PET can accurately diagnose AD; however, at this time, there is no evidence to suggest that a diagnosis of AD with PET alters the clini …
-
Hippocampal Tail Volume as a Predictive Biomarker of Antidepressant Treatment Outcomes in Patients With Major Depressive Disorder: A CAN-BIND ReportN Nogovitsyn et al. Neuropsychopharmacology 45 (2), 283-291. PMID 31610545.Finding a clinically useful neuroimaging biomarker that can predict treatment response in patients with major depressive disorder (MDD) is challenging, in part because of …
-
Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet]Swedish Council on Health Technology Assessment. PMID 28876770. - ReviewAdditional research on dementia disorders is required in several areas:
How the various disorders progress
… -
Magnetic Resonance Imaging Application in the Area of Mild and Acute Traumatic Brain Injury: Implications for Diagnostic Markers?A Toth. PMID 26269902. - ReviewMild traumatic brain injury (mTBI) causes brain damage generally invisible for conventional imaging methods. Its diagnosis mostly relies on the patient’s history, subject …
References
-
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): APA; 2013.
-
- Fonseka TM, MacQueen GM, Kennedy SH. Neuroimaging biomarkers as predictors of treatment outcome in major depressive disorder. J Affect Disord. 2017;233:21–35. - PubMed
LinkOut - more resources
Full Text Sources